幽门螺杆菌感染相关胃癌的蛋白酪氨酸激酶SHP-2的表达升高

IM To explore the alteration of Tyrosine phosphatase SHP-2 (PTPN11) protein expression in gastric cancer and to assess its prognostic values. METHODS Three hundred and five consecutive cases of gastric cancer were enrolled in the study. SHP-2 expression was carried out in 305 gastric cancer specimen, of which 83 had paired adjacent normal gastric mucus samples using a tissue microarray immunohistochemistry method. Correlations were analyzed between expression levels of SHP-2 protein and tumor parameters or clinical outcomes. Serum anti- Helicobacter pylori (H.pylori) IgG was detected by enzyme-linked immunosorbent assay (ELISA) method. Cox proportional hazards model was used to evaluate prognostic values by compassion of the expression levels of SHP-2 and disease-specific survivals in patients. RESULTS SHP-2 staining was mainly found diffuse in the cytoplasm and the weak staining was also observed in the nucleus in gastric mucosa cells. 32.5% of normal epithelial specimen and 62.6% of gastric cancer specimen were identified to stain with SHP-2 antibody positively (P < 0.001). Though SHP-2 staining intensities were observed stronger in the H.pylori (+) group compared to the H.pylori (-) group, however, no statistically significant difference was found in the expression levels of SHP-2 between H.pylori (+) and H.pylori (-) gastric cancer (P=0.40). The SHP-2 expression in gastric cancer was not significantly associated with cancer stages, lymph node metastases, and distant metastasis of the tumors (P=0.34, P=0.17, P=0.52). Multivariate analysis demonstrated no correlation between SHP-2 expression and disease free survival (P=0.86). CONCLUSION Increased expression of SHP-2 protein in gastric cancer specimen suggesting the aberrant upregulation of SHP-2 protein might play an important role in the gastric carcinogenesis.